The US FDA has beefed up its Office of Generic Drugs (OGD), affording the division ‘super-office’ status in a move that reflects the growing importance of non-branded medicines in the world's biggest market.
A study in the Journal of the American Medical Association (JAMA) claiming there is no evidence that brandname cardiovascular drugs are superior to their generic counterparts, despite claims to the contrary.
The Food and Drug Administration are set to introduce a series of
measures that will accelerate the review process for generic drugs,
placing a priority on therapies that would address a public health
emergency or nationwide shortage.